… sclerosis” for clinical trials of disease-modifying treatments in both primary progressive
and secondary progressive multiple sclerosis and studies of high-dose biotin and relevant …

… Breakthrough disease under high-dose biotin in progressive multiple sclerosis. European
Comittee on Treatment and Research in Multiple Sclerosis Annual Conference; Paris: …

… enhance the production of adenosine triphosphate (ATP), which may be … and safety of
high-dose biotin (HDB) in multiple sclerosis via a … Secondary progressive multiple sclerosis …

… The trial randomly assigned 642 participants with primary or secondary progressive multiple
sclerosis (297 [46%] men and 345 [54%] women) either MD1003 (n=326) or placebo (n=316…

… High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS).
Some reports have suggested that HDB treatment may be associated with an increased …

… Patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) who …
high-dose biotin treatment was started. However, 12 months into the high-dose biotin treatment…

… The role of the secondary progressive form in treatment response should be interpreted with
caution according to the large credibility interval (OR 0.42; 95% CI [0.07; 1.27]). Normalized …

… progressive MS and 9 patients with secondary progressive MS… Patients opposed to standard
disease-modifying drugs and … -based, such as high-dose biotin, may not be referred to a …

… regenerative therapy in multiple sclerosis, the concept of high-dose biotin (HDB) treatment
(… of HDB in patients with primary and secondary progressive MS revealed promising results (…

… while taking biotin, the results of the study excluded the possibility of an increased risk of
relapses during biotin therapy [23]. In preliminary studies, high-dose biotin was considered a …